LANGLEBIGE ALPHA-HÄMOLYSIN-NANOPOREN

European patent · EP3478706 · In force

Register entry

Publication number
EP3478706
Application number
EP17740304
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 28, 2017
Published
May 8, 2019
Granted
Feb 9, 2022
Protection ends at the latest
Jun 27, 2037
Next annual fee due
Jun 30, 2027
IPC classes
C07K 14/31 (2006.01)
Priority
US 201662357230 P 30.06.2016
PCT application
PCT/EP2017/065972 28.06.2017
PCT publication
WO2018/002125 04.01.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Dec 21, 2022

    Change

    Published in Swissreg on 21.12.2022

  6. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  7. Feb 9, 2022

    Granted

    Published in Swissreg on 09.02.2022

Parties

Holder

F. Hoffmann-La Roche AG

Grenzacherstrasse 124, 4070 Basel

Inventor

PORTER, Marshall

Petaluma California 94952, US

HARRIS, Corissa

Redwood City, CA 94063, US

DIPIETRO, Matthew

Gilroy California 95020, US

AMBROSO, Mark

San Diego California 92128, US

CRAIG, Timothy

0281 Oslo, NO

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.